TY - JOUR
T1 - The effect of VIP/PACAP family of peptides on pancreatic blood flow and secretion in conscious dogs
AU - Ito, Osamu
AU - Naruse, Satoru
AU - Kitagawa, Motoji
AU - Ishiguro, Hiroshi
AU - Ko, Shigeru
AU - Nakajima, Morio
AU - Hayakawa, Tetsuo
N1 - Funding Information:
We wish to thank Dr. T. Ozaki, National Institute for Physiological Sciences, for his support, and Dr. V. Wray, Gesellschaft für Biotechnologische Forschung, for his advice. This work was supported by grants from the Ministry of Education, Science and Culture, Japan and the Pancreatic Research Foundation of Japan to S.N.
PY - 1998/11/30
Y1 - 1998/11/30
N2 - The effects of PACAP-38, PACAP-27, VIP and secretin on pancreatic blood flow were compared with those of meals in five conscious dogs using an ultrasound transit-time blood flow meter. All peptides (1-100 pmol/kg) induced dose-related increases of pancreatic blood flow, and fluid and bicarbonate secretion. Only PACAPs stimulated protein secretion. Both PACAPs at doses which did not stimulate pancreatic secretion, induced significant pancreatic vasodilatation. VIP was less potent than PACAP-38 and PACAP-27 at lower doses (1-25 pmol/kg), but was similar to PACAPs at higher doses. The maximal effects of PACAPs and VIP were comparable to those observed after meals. Secretin was a significant but weak vasodilator. When pancreatic secretion was maximally stimulated by secretin, a reduction of vascular resistance was 75% of postprandial peak levels. PACAP(6-38), a competitive antagonist of PACAP, inhibited pancreatic vascular responses to PACAPs, but not those to VIP and secretin. Its inhibitory effects on protein response to PACAPs were not significant. Atropine inhibited pancreatic protein but not the vascular effect of PACAP-27. Pancreatic vasodilatation by PACAPs appears to be mediated by both PACAP-specific and VIP/PACAP common receptors in dogs. PACAP, like VIP, is a good candidate for a mediator of atropine-resistant vasodilatation of the pancreas. Copyright (C) 1998 Elsevier Science B.V.
AB - The effects of PACAP-38, PACAP-27, VIP and secretin on pancreatic blood flow were compared with those of meals in five conscious dogs using an ultrasound transit-time blood flow meter. All peptides (1-100 pmol/kg) induced dose-related increases of pancreatic blood flow, and fluid and bicarbonate secretion. Only PACAPs stimulated protein secretion. Both PACAPs at doses which did not stimulate pancreatic secretion, induced significant pancreatic vasodilatation. VIP was less potent than PACAP-38 and PACAP-27 at lower doses (1-25 pmol/kg), but was similar to PACAPs at higher doses. The maximal effects of PACAPs and VIP were comparable to those observed after meals. Secretin was a significant but weak vasodilator. When pancreatic secretion was maximally stimulated by secretin, a reduction of vascular resistance was 75% of postprandial peak levels. PACAP(6-38), a competitive antagonist of PACAP, inhibited pancreatic vascular responses to PACAPs, but not those to VIP and secretin. Its inhibitory effects on protein response to PACAPs were not significant. Atropine inhibited pancreatic protein but not the vascular effect of PACAP-27. Pancreatic vasodilatation by PACAPs appears to be mediated by both PACAP-specific and VIP/PACAP common receptors in dogs. PACAP, like VIP, is a good candidate for a mediator of atropine-resistant vasodilatation of the pancreas. Copyright (C) 1998 Elsevier Science B.V.
KW - Atropine
KW - PACAP(6-38)
KW - PACAP/VIP receptor
KW - Postprandial pancreatic blood flow
KW - Secretin
UR - http://www.scopus.com/inward/record.url?scp=0032583178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032583178&partnerID=8YFLogxK
U2 - 10.1016/S0167-0115(98)00135-9
DO - 10.1016/S0167-0115(98)00135-9
M3 - Article
C2 - 9879753
AN - SCOPUS:0032583178
SN - 0167-0115
VL - 78
SP - 105
EP - 112
JO - Regulatory Peptides
JF - Regulatory Peptides
IS - 1-3
ER -